

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Farmaforce Limited
ABN	95 167 748 843

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	George Elias
Date of last notice	04/06/18

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest						
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Potential Beneficiary of <ul style="list-style-type: none"> • Elinvest Pty Ltd <Elias Family A/C> • Seftias Pty Ltd <G & V A/C> 						
Date of change	10/09/2018						
No. of securities held prior to change	838,159 Fully Paid Ordinary Shares 125,000 Options						
Class	Fully Paid Ordinary Shares						
Number acquired	<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; text-align: right;">10/09/2018</td> <td style="width: 50%; text-align: right;">2,392</td> </tr> <tr> <td style="text-align: right;">10/09/2018</td> <td style="text-align: right;">2,608</td> </tr> <tr> <td style="text-align: right;">10/09/2018</td> <td style="text-align: right;">156,841</td> </tr> </table>	10/09/2018	2,392	10/09/2018	2,608	10/09/2018	156,841
10/09/2018	2,392						
10/09/2018	2,608						
10/09/2018	156,841						
Number disposed							
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; text-align: right;">2,392</td> <td style="width: 50%; text-align: left;">at \$0.135000</td> </tr> <tr> <td style="text-align: right;">2,608</td> <td style="text-align: left;">at \$0.135414</td> </tr> <tr> <td style="text-align: right;">156,841</td> <td style="text-align: left;">at \$0.139924</td> </tr> </table>	2,392	at \$0.135000	2,608	at \$0.135414	156,841	at \$0.139924
2,392	at \$0.135000						
2,608	at \$0.135414						
156,841	at \$0.139924						
No. of securities held after change	1,000,000 Fully Paid Ordinary Shares 125,000 Options						

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade
---	-----------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.